Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Is it time to retire fragile X testing as a first-tier test for developmental delay, intellectual disability, and autism spectrum disorder?

Mullegama SV, Klein SD, Nguyen DC, Kim A, Signer R, Fox M, Dorrani N, Hendershot A, Mardach R, Suddath R, Dipple K, Vilain E, Wong DA, Deignan JL, D Cederbaum S, Grody WW, Martinez-Agosto JA.

Genet Med. 2017 Dec;19(12). doi: 10.1038/gim.2017.146. Epub 2017 Sep 21. No abstract available.

PMID:
28933790
2.

Diagnostic profiles and clinical characteristics of youth referred to a pediatric mood disorders clinic.

Weintraub M, Youngstrom EA, Marvin SE, Podell JL, Walshaw PD, Kim EY, Suddath RL, Forgey-Borlick MJ, Matkevich BN, Miklowitz DJ.

J Psychiatr Pract. 2014 Mar;20(2):154-62. doi: 10.1097/01.pra.0000445251.20875.47.

3.

An emergency department intervention for linking pediatric suicidal patients to follow-up mental health treatment.

Asarnow JR, Baraff LJ, Berk M, Grob CS, Devich-Navarro M, Suddath R, Piacentini JC, Rotheram-Borus MJ, Cohen D, Tang L.

Psychiatr Serv. 2011 Nov;62(11):1303-9. doi: 10.1176/ps.62.11.pss6211_1303.

4.

Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings.

Lynch FL, Dickerson JF, Clarke G, Vitiello B, Porta G, Wagner KD, Emslie G, Asarnow JR Jr, Keller MB, Birmaher B, Ryan ND, Kennard B, Mayes T, DeBar L, McCracken JT, Strober M, Suddath RL, Spirito A, Onorato M, Zelazny J, Iyengar S, Brent D.

Arch Gen Psychiatry. 2011 Mar;68(3):253-62. doi: 10.1001/archgenpsychiatry.2011.9.

5.

Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample.

Vitiello B, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller MB, Birmaher B, Ryan ND, Kennard B, Mayes TL, DeBar L, Lynch F, Dickerson J, Strober M, Suddath R, McCracken JT, Spirito A, Onorato M, Zelazny J, Porta G, Iyengar S, Brent DA.

J Clin Psychiatry. 2011 Mar;72(3):388-96. doi: 10.4088/JCP.09m05885blu.

6.

A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder.

McGough JJ, McCracken JT, Loo SK, Manganiello M, Leung MC, Tietjens JR, Trinh T, Baweja S, Suddath R, Smalley SL, Hellemann G, Sugar CA.

J Am Acad Child Adolesc Psychiatry. 2009 Dec;48(12):1155-64. doi: 10.1097/CHI.0b013e3181bc72e3.

7.

Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.

Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, Vitiello B, Iyengar S, Birmaher B, Ryan ND, Zelazny J, Onorato M, Kennard B, Mayes TL, Debar LL, McCracken JT, Strober M, Suddath R, Leonard H, Porta G, Keller MB.

Am J Psychiatry. 2009 Apr;166(4):418-26. doi: 10.1176/appi.ajp.2008.08070976. Epub 2009 Feb 17. Erratum in: Am J Psychiatry. 2019 Sep 1;176(9):764.

8.

Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response.

Asarnow JR, Emslie G, Clarke G, Wagner KD, Spirito A, Vitiello B, Iyengar S, Shamseddeen W, Ritz L, Birmaher B, Ryan N, Kennard B, Mayes T, DeBar L, McCracken J, Strober M, Suddath R, Leonard H, Porta G, Keller M, Brent D.

J Am Acad Child Adolesc Psychiatry. 2009 Mar;48(3):330-339. doi: 10.1097/CHI.Ob013e3181977476.

9.

Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome.

McCracken JT, Suddath R, Chang S, Thakur S, Piacentini J.

J Child Adolesc Psychopharmacol. 2008 Oct;18(5):501-8. doi: 10.1089/cap.2007.135.

10.

Pediatric emergency department suicidal patients: two-site evaluation of suicide ideators, single attempters, and repeat attempters.

Asarnow JR, Baraff LJ, Berk M, Grob C, Devich-Navarro M, Suddath R, Piacentini J, Tang L.

J Am Acad Child Adolesc Psychiatry. 2008 Aug;47(8):958-66. doi: 10.1097/CHI.0b013e3181799ee8.

PMID:
18596552
11.

Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.

Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J.

JAMA. 2008 Feb 27;299(8):901-13. doi: 10.1001/jama.299.8.901.

12.

Violent fantasy, dangerousness, and the duty to warn and protect.

Gellerman DM, Suddath R.

J Am Acad Psychiatry Law. 2005;33(4):484-95.

PMID:
16394225
13.

Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.

McGough JJ, Pataki CS, Suddath R.

Expert Rev Neurother. 2005 Jul;5(4):437-41. Review.

PMID:
16026226
14.

Emergency department management of suicidal adolescents.

Kennedy SP, Baraff LJ, Suddath RL, Asarnow JR.

Ann Emerg Med. 2004 Apr;43(4):452-60. Review.

PMID:
15039687
15.

A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder.

Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL.

Arch Gen Psychiatry. 2003 Sep;60(9):904-12.

PMID:
12963672
16.

Integrated family and individual therapy for bipolar disorder: results of a treatment development study.

Miklowitz DJ, Richards JA, George EL, Frank E, Suddath RL, Powell KB, Sacher JA.

J Clin Psychiatry. 2003 Feb;64(2):182-91.

PMID:
12633127
17.

Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy.

Miklowitz DJ, Simoneau TL, George EL, Richards JA, Kalbag A, Sachs-Ericsson N, Suddath R.

Biol Psychiatry. 2000 Sep 15;48(6):582-92.

PMID:
11018229
18.

Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p).

Denicoff KD, Smith-Jackson EE, Disney ER, Suddath RL, Leverich GS, Post RM.

J Psychiatr Res. 1997 Sep-Oct;31(5):593-603.

PMID:
9368200
19.

Dopamine-responsive neurotrophic factor in schizophrenia.

Hedges S, El-Mallakh RS, Carvey PM, Suddath RL, Wyatt RJ.

Schizophr Res. 1995 Dec;18(1):83-4. No abstract available.

PMID:
8929765
20.

A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: II. Correlations with psychopathology.

Issa F, Kirch DG, Gerhardt GA, Bartko JJ, Suddath RL, Freedman R, Wyatt RJ.

Psychiatry Res. 1994 Jun;52(3):251-8.

PMID:
7991719
21.

A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. Comparisons with healthy control subjects and neuroleptic-treated/unmedicated pairs analyses.

Issa F, Gerhardt GA, Bartko JJ, Suddath RL, Lynch M, Gamache PH, Freedman R, Wyatt RJ, Kirch DG.

Psychiatry Res. 1994 Jun;52(3):237-49.

PMID:
7991718
22.

CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.

Breslin NA, Suddath RL, Bissette G, Nemeroff CB, Lowrimore P, Weinberger DR.

Schizophr Res. 1994 Apr;12(1):35-41.

PMID:
7517175
23.

Medial temporal lobe structures in schizophrenia: relationship of size to duration of illness.

Marsh L, Suddath RL, Higgins N, Weinberger DR.

Schizophr Res. 1994 Feb;11(3):225-38.

PMID:
8193061
24.
25.

Event-related potential abnormalities correlate with structural brain alterations and clinical features in patients with chronic schizophrenia.

Egan MF, Duncan CC, Suddath RL, Kirch DG, Mirsky AF, Wyatt RJ.

Schizophr Res. 1994 Feb;11(3):259-71.

PMID:
7910755
26.

Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects.

el-Mallakh RS, Suddath RL, Wyatt RJ.

Prog Neuropsychopharmacol Biol Psychiatry. 1993 May;17(3):383-91.

PMID:
8475320
27.

6-[18F]fluoro-L-dopa and cerebral blood flow in unilaterally MPTP-treated monkeys.

Doudet DJ, Wyatt RJ, Cannon-Spoor E, Suddath R, McLellan CA, Cohen RM.

J Neural Transplant Plast. 1993 Jan-Mar;4(1):27-38.

28.

Cerebrospinal fluid and serum levels of neuron-specific enolase in patients with schizophrenia.

Egan MF, el-Mallakh RS, Suddath RL, Lohr JB, Bracha HS, Wyatt RJ.

Psychiatry Res. 1992 Aug;43(2):187-95.

PMID:
1357702
30.

Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia.

Kirch DG, Alexander RC, Suddath RL, Papadopoulos NM, Kaufmann CA, Daniel DG, Wyatt RJ.

J Neural Transm Gen Sect. 1992;89(3):219-32.

PMID:
1389005
31.

Evidence against progression of in vivo anatomical abnormalities in schizophrenia.

Abi-Dargham A, Jaskiw G, Suddath RL, Weinberger DR.

Schizophr Res. 1991 Oct;5(3):210. No abstract available.

PMID:
1760399
32.

A clinical trial of nifedipine in schizophrenia and tardive dyskinesia.

Suddath RL, Straw GM, Freed WJ, Bigelow LB, Kirch DG, Wyatt RJ.

Pharmacol Biochem Behav. 1991 Jul;39(3):743-5.

PMID:
1686106
33.

Crow's 'lateralization hypothesis' for schizophrenia.

Weinberger DR, Suddath RL, Casanova MF, Torrey EF, Kleinman JE.

Arch Gen Psychiatry. 1991 Jan;48(1):85-7. No abstract available.

PMID:
1984765
34.
35.

Corpus callosum curvature in schizophrenic twins.

Casanova MF, Zito M, Goldberg TE, Suddath RL, Torrey EF, Bigelow LB, Sanders RD, Weinberger DR.

Biol Psychiatry. 1990 Jul 1;28(1):83-4. No abstract available.

PMID:
2375946
36.

Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia.

Suddath RL, Christison GW, Torrey EF, Casanova MF, Weinberger DR.

N Engl J Med. 1990 Mar 22;322(12):789-94. Erratum in: N Engl J Med 1990 May 31;322(22):1616.

37.

Quantitative shape analysis of the temporal and prefrontal lobes of schizophrenic patients: a magnetic resonance image study.

Casanova MF, Goldberg TE, Suddath RL, Daniel DG, Rawlings R, Lloyd DG, Loats HL, Kleinman JE, Weinberger DR.

J Neuropsychiatry Clin Neurosci. 1990 Fall;2(4):363-72.

PMID:
2136388
38.

Medication effect on lymphocyte morphology in schizophrenia.

Torrey EF, Upshaw YD, Suddath R.

Schizophr Res. 1989 Jul-Oct;2(4-5):385-90.

PMID:
2577275
39.

Shape analysis of the middle cranial fossa of schizophrenic patients. A computerized tomographic study.

Casanova MF, Daniel DG, Goldberg TE, Suddath RL, Weinberger DR.

Schizophr Res. 1989 Jul-Oct;2(4-5):333-8.

PMID:
2487174
40.

Temporal lobe pathology in schizophrenia: a quantitative magnetic resonance imaging study.

Suddath RL, Casanova MF, Goldberg TE, Daniel DG, Kelsoe JR Jr, Weinberger DR.

Am J Psychiatry. 1989 Apr;146(4):464-72.

PMID:
2929746
41.

Met5-enkephalin-Arg6-Gly7-Leu8 immunoreactivity in rat and human cerebrospinal fluid: influence of neuroleptic drugs and electroconvulsive shock.

Iadarola MJ, Flores CM, Cadet JL, Suddath R, Illowsky B, Berman KF.

Brain Res. 1988 Nov 22;474(1):75-85.

PMID:
2905617
42.

Persistently decreased brain dopamine levels and cocaine.

Wyatt RJ, Karoum F, Suddath R, Fawcett R.

JAMA. 1988 May 27;259(20):2996. No abstract available.

PMID:
3367471
43.

Edward G. Billings, M.D.: pioneer of consultation-liaison psychiatry.

Thompson TL 2nd, Suddath RL.

Psychosomatics. 1987 Mar;28(3):153-6. No abstract available.

PMID:
3324158

Supplemental Content

Loading ...
Support Center